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Abstract: Alkylation of malonamic esters provides a direct approach to derivatives of 
suberoylanilide hydroxamic acid (SAHA) that are branched at the amide carbon atom, a 
location pivotal for enhancing biological and therapeutic activity. Alkylations use NaH in 
THF followed by addition of the ester of 6-bromohexanoic acid; no protection of the amidic 
NH group is necessary. By this means, carboxylic acid, ester, amide, hydroxymethyl and 2-
benzimidazolyl branching units have been appended to the SAHA backbone. Routes to vary 
one of the branching units at a time have been developed. 
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1. Introduction 
     Hydroxamic acids1 play a pivotal role as inhibitors of metal-dependent enzymes including 
matrix metalloproteinases and histone deacetylases (HDACs).2-4 The hydrolytic action of 
histone deacetylases requires coordination of a terminally acetylated lysine residue, usually to 
zinc(II) in the catalytic site, prior to hydrolysis;5 this is inhibited by powerful metal chelators, 
including hydroxamic acid derivatives compatible with the HDAC catalytic site, tunnel and 
protein periphery. The extent of acetylation levels of terminal lysine residues on histone 
protein is a major epigenetic regulator of gene expression; up-regulation of HDACs results in 
aberrant gene repression frequently associated with cancer. HDACs have also recently been 
shown to affect DNA replication and DNA repair.3 Several HDAC inhibitors have entered 
clinical trials for the treatment of cancers. HDAC inhibitors are also used in the treatment 
Huntington’s disease and show potential for the treatment of other neurodegenerative diseases 
and inflammation.2-4 
     Hydroxamic acids are the largest class of HDAC inhibitors.2 Of the four HDAC inhibitors 
approved by the FDA (Fig. 1), three are hydroxamic acids: suberoylanilide hydroxamic acid 
(SAHA), used in early epigenetic studies, is marketed as Zolinza® for the treatment of  
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cutaneous T-cell lymphoma;6 belinostat is used for the treatment of peripheral T-cell 
lymphoma,7 and panobinostat for the treatment of multiple myeloma.8 Currently, most HDAC 
inhibitors in clinical trials are relatively nonselective among the nearly 20 known mammalian 
HDAC isozymes. The provision of more selective HDAC inhibitors with lower toxicity and 
greater potency are major unmet needs in the area of HDAC therapy.9,10 The present work 
describes the synthesis of branched hydroxamic acids, and in particular branched analogues of 
SAHA, given its pivotal roles as a probe in structural biology,11 in epigenetic studies,12 and its 
continued use as an epigenetic anti-cancer agent. 
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Figure 1. FDA-approved HDAC inhibitors. 
2. Results and Discussion                                               
     Branching of HDAC inhibitors in the region that bind to the protein surface can enhance 
inhibitor potency and has been predicted to improve isozyme selectivity.13 The branched 
inhibitor 4 was found to be at least 6-fold more potent14 than SAHA in an in vitro enzyme 
assay, and to be up to 20-fold more potent in cellular antiproliferation assays against a panel 
of nine multiple myeloma and non-Hodgkin’s lymphoma cell lines.15 The greatly increased 
overall inhibition of HDACs (pan-HDAC inhibition) superior pre-clinical data compared to 
SAHA can be attributed to the contacts made with the enzyme periphery by the additional 
anilide moiety. Improvements to the first two steps of the route to the branched hydroxamic 
acid 4 are here described (Scheme 1), enabling a range of symmetrical malonamides to be 
synthesised in two laboratory steps from the malonic acid 2. 
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Scheme 1. Synthesis of a symmetrical bis-malonamide hydroxamic acid.14 Reagents and conditions:  
a NaH (1.1 equiv.) first added to di-tert-butyl malonate (1 equiv.), THF, 20 °C, 20 min then reflux,  
  16 h, 74%. 
b CF3CO2H (6 equiv.), CH2Cl2, 20 °C, 16 h, 99%. 
c SOCl2 (6 equiv.), benzene, reflux, 2 h14 then  
d PhNH2 (6 equiv.), pyridine (3 equiv.), CH2Cl2, 20 °C, 17 h, 76%.14  
e NaOMe, (3 equiv.) and HONH2 (2 equiv.), MeOH, 20 °C, 16 h, 68%.14  
 
Alkylation of N-disubstituted malonamides with linear alkyl halides has been recently 
described.16,17 In contrast, few alkylations of NH-malonamides have been described, which to 
our knowledge have been limited to benzylic halides18,19 and diiodomethane,20 being activated 
halides rather than typical linear alkyl halides. Notwithstanding that, the proposed route to 
branched derivatives of SAHA was by alkylation of a suitable malonamic ester. The strategy 
required the compatibility of the trifunctional compounds with reagents and with a 
transformation of only one group per step, for most sequences. The Boc-protected malonamic 
ester 5 was selected for the start of the investigation since differential reaction of the ester 
groups was expected to be reliable. Pleasingly, efficient alkylation of malonamic ester 5 was 
accomplished by treatment with NaH in THF followed by addition of ethyl 6-bromohexanoate 
to give the key intermediate 6 in 74% yield (Scheme 2). This compound provided access to a 
range of new trifunctional compounds, including three hydroxamic acids: direct conversion of 
6 into the C-8 hydroxamic acid was achieved using excess aqueous hydroxylamine in the 
presence of a methanolic solution of 1M KOH and affording 7 in 29% yield. Cleavage of the 
tert-butyl group in 1:1 TFA:dichloromethane afforded the carboxylic acid 8, unusual in also 
containing amide and a hydroxamic acid units. Under similar conditions, cleavage of the tert-
butyl group in ester 6 afforded the desired carboxylic acid 9 which was selectively reduced 
with NaBH4 in methanol to give the hydroxymethyl ester 10 (77%). This ester underwent 
conversion into the corresponding hydroxamic acid 11 by treatment with 5 equivalents of 
hydroxylamine in methanolic KOH; although conversion was efficient, isolation proved 
difficult, and only 12% was recovered. 
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Scheme 2. Synthesis of branched derivatives of SAHA. Reagents and conditions:  
a NaH (1.1 equiv.), ethyl 6-bromohexanoate (1 equiv.), THF, 70 °C, 18 h, 74%. 
b 50% aqueous HONH2 (10 equiv.), 1 M KOH in MeOH, THF, 20 °C, 1 h, 29%. 
c 1:1 CF3CO2H:CH2Cl2, 20 °C, 6 h, 80%. 
d ClCO2Et (1.5 equiv.), Et3N (1.2 equiv), THF, 0 °C, 30 min then NaBH4 (3 equiv.),21 MeOH, 10 °C,  
  1.5 h, 77%. 
e Aqueous 50% HONH2 (5 equiv.), 1M KOH in MeOH, THF, 20 °C, 1.5 h, 12%. 
f 1:1 CF3CO2H:CH2Cl2, 20 °C, 30 min, 80%. 
 
     The benzimidazole ring system as a capping group for HDAC inhibitors has shown potential 
in models of pancreatic cancer,22 and so was used in the present study as a representative 
heterocycle. Having trifunctional acid 9 available in quantity, the introduction of a range of 
amides at the branching position was feasible, and hence a series of the corresponding 
hydroxamic acids should be accessible. In a relatively challenging test of the protocol, the 
carboxylic acid 9 was reacted with tert-butyl N-(2-aminophenyl)carbamate using N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC.HCl) and 1-
hydroxybenzotriazole monohydrate (HOBt), giving the malonamide 12 in 66% yield. Ring 
closure was effected by heating in acetic acid at reflux, affording the benzimidazole 13 (77%). 
However, direct conversion of ester 13 into the desired hydroxamic acid 15 upon treatment 
with hydroxylamine and KOH in aqueous methanol resulted in difficulties in purification of the 
hydroxamic acid which was too polar for column chromatography and could not be 
satisfactorily purified by recrystallisation. This was circumvented by Boc-protection of 13 to 
give 14 and treatment with the standard solution containing hydroxylamine. Concomitant 
conversion into the hydroxamate and cleavage of the Boc group occurred, affording in one 
laboratory step the desired deprotected hydroxamic acid 15 in 50% yield. Scheme 3 established 
that differential amidation of 9 could be achieved, and given that ester to hydroxamic acid 
conversion is tolerated by a range of functional groups, is a likely general route to 
unsymmetrical malonamides and their corresponding hydroxamic acids. Additionally, 
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heterocyclisation involving the amide group should permit a variety of heterocycles to be 
installed using well-established ring-closures. 
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Scheme 3. Synthesis of a branched 2-benzimidazolinyl derivative of SAHA. Reagents and conditions:  
a tert-Butyl N-(2-aminophenyl)carbamate (1 equiv.), EDC.HCl (1.1 equiv.), HOBt (1.1 equiv.), Et3N 
  (2.2 equiv), DMF, 20 °C, 18 h, 66%. 
b TFA, reflux, 2 h, 75%. 
c Di-tert-butyl dicarbonate (1.5 equiv.), THF, 20 °C, 7 d, 64% conversion. 
d Aqueous 50% HONH2 (10 equiv.), 1 M KOH in MeOH, THF, 20 °C, 6 h, 50%. 
 
     A more convergent approach to SAHA analogs containing heterocyclic rings at the branch 
point than that of Scheme 3 could be achieved if the order of reactions could be reversed, so 
that the heterocycle is installed earlier on, as an acetate ester such as 17 (Scheme 4). This 
sequence would also be desirable when other functionality present (or stereocentres) is 
incompatible with the conditions for the formation of heteroaromatic rings, usually quite harsh. 
The malonamic ester 16, formed by acylation of 1,2-phenylenediamine with 3-tert-butoxy-3-
oxopropanoic acid using N,N’-dicyclohexylcarbodiimide (DCC), underwent heterocylisation in 
acetic acid at 90 °C (96%) to give the benzimidazole 17. Boc-protection gave the derivative 18 
(97%) which was deprotonated using NaH in THF, and underwent alkylation using ethyl 6-
bromohexanoate, albeit in low yield (33%); the N-Boc protected ester 19 underwent efficient 
conversion into the hydroxamic acid, again accompanied by selective N-Boc-deprotection, to 
give the branched hydroxamic acid 20 in 67% yield. These two strategies are complementary; 
different heterocycles may be attached to the same amide using Scheme 3, but different amides 
may also be attached to the same heterocycle using Scheme 4. 
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Scheme 4. Synthesis of a branched hydroxamic acid with a 2-benzimidazolyl capping group. Reagents 
and conditions: 
a 1,2-Phenylenediamine (1 equiv.), N,N’-dicyclohexylcarbodiimide (1.1 equiv.), MeCN, 20 °C, 20 min,  
  50%. 
b AcOH, 90 °C, 1 h, 96%. 
c Di-tert-butyl dicarbonate (1.2 equiv.), THF, 20 °C, 3 d, 97%. 
d NaH (1.1 equiv.), THF, 60 °C, 18 h, 33%. 
e 50% aqueous HONH2 (10 equiv.), 1 M KOH in MeOH, THF, 20 °C, 30 min, 67%. 
 
     For future comparison of biological activities of branched versus non-branched hydroxamic 
acids, two linear hydroxamic acids were prepared, the first being the parent compound 22 of 
the above branched benzimidazole derivatives, synthesised succinctly according to Scheme 5. 
For comparison with a heterocyclic analog of SAHA constrained by annulation and lacking an 
NH group, which in the case of SAHA is required for hydrogen-bonding with an aspartate 
residue (Asp99 in HDAC1), pyrimidinone 25 was selected, since it also contains a cyclic 
symmetrical malonamide motif.  
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Scheme 5. Succinct synthesis of a linear hydroxamic acid with a 2-benzimidazolyl capping group. 
Reagents and conditions:  
a Suberic anhydride (1 equiv.), THF, 20 °C, 20 min; then 4% conc. H2SO4 in EtOH, 29%. 
b Aqueous 50% HONH2, 1 M KOH in MeOH, THF, 20 °C, 6 h, 61%. 
 
Attempts to form the pyrimidinone 24 via the diacid dichloride of 2, or by activation of the 
carboxylic acid groups of 2 with ethyl chloroformate were unsuccessful. The synthesis of 
pyrimidinone 24 was eventually accomplished by reaction of diacid 2 with 2,4,6-
trichlorophenol in the presence of POCl323 to give the ester 23 which with N,N-diethyl-N’-
phenylguanidine at 150 °C underwent rapid conversion into the desired pyrimidinone 25.  
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Scheme 6. Synthesis of a SAHA analog constrained by annulation. Reagents and conditions:  
a CF3CO2H (6 equiv.), CH2Cl2, 20 °C, 24 h, 99%. 
b 2,4,6-Trichlorophenol (2 equiv.), POCl3 (2.6 equiv.), 100 °C, 5 h, 49%. 
c N,N-Diethyl-N’-phenylguanidine (1 equiv.), 5 min, 150 °C, 68%. 
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d Aqueous 50% HONH2 (10 equiv.), 1M KOH in MeOH, THF, 20 °C, 2 h, 51%. 
 
3. Conclusion 
Alkylation of malonamic esters has been shown to provide a direct approach to derivatives of 
suberoylanilide hydroxamic acid (SAHA) that are branched alpha to the amide carbon atom, 
a location pivotal for enhancing biological and therapeutic activity. Deprotonation of 
malonamic esters was conveniently achieved using NaH in THF followed by treatment with 
an ester of 6-bromohexanoic acid; no protection of the amidic NH group was necessary. By 
this means, carboxylic acid, ester, amide, hydroxymethyl and 2-benzimidazolyl branching 
units have been appended to the SAHA backbone. A 2-benzimidazolyl unit can be added by 
cyclisation, or alternatively by alkylation of a 2-benzimidazolyl acetate. These 
complementary routes enable variation of either branching unit at a time: the heterocyclic 
branching unit or alternatively the carboxy chain. Improvements to synthesis of branched 
hydroxamic acids from malonyl derivatives have also been achieved, and in addition the 
synthesis of a new SAHA derivative constrained by heterocyclic annulation. 
4. Experimental Section 
4.1 General. All moisture-sensitive reactions were performed under an atmosphere of nitrogen 
and the glassware was pre-dried in an oven (130 °C). Evaporation refers to the removal of 
solvent under reduced pressure. Melting points were measured by a microscope hot-stage 
Electrothermal 9100 apparatus. Infra-red (IR) spectra were recorded on a Perkin-Elmer PE-983 
spectrophotometer. 1H NMR spectra were recorded on a Bruker AC300 (300 MHz) 
spectrometer or a Bruker AMX 500 (125 MHz) spectrometer; data are reported in parts per 
million (δ). Coupling constants (J) are given in Hertz (Hz). The following abbreviations were 
used in signal assignments: singlet (s), broad singlet (br s), doublet (d), triplet (t), quartet (q), 
and multiplet (m). 13C NMR spectra were recorded on Bruker AMX300 (75 MHz), Bruker 
AMX400 (100 MHz) or Bruker AMX 500 (125 MHz) spectrometers; data are reported in parts 
per million (δ), with CHCl3 as an internal standard. Mass spectra were recorded on a VG7070H 
mass spectrometer with Finigan Incos II data system at University College London. Optical 
rotations were measured using a Perkin-Elmer 343 digital polarimeter. Thin-layer 
chromatography was performed on Merck 0.2 mm aluminium-backed silica gel 60 F254 plates 
and visualised by UV (254 nm) or by staining with alkaline potassium permanganate spray and 
subsequent heating. Flash column chromatography was performed using Merck 0.040-0.063 
mm, 230-400 mesh silica gel.  
The following compounds were prepared according to the literature: tert-butyl 3-oxo-3-
(phenylamino)propanoate (5);14 tert-butyl N-(2-aminophenyl)carbamate;24 tert-butyl 3-
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oxopropanoate;25 oxonane-2,9-dione;26 bis(2,4,6-trichlorophenyl) malonate;23 N,N-diethyl-N’-
phenylguanidine.27 
4.2 Synthesis  
6-Ethyl 1,1-bis(tert-butyl)hexane-1,1,6-tricarboxylate (1). To a solution of di-tert-butyl 
malonate (5.0 g, 23.1 mmol) in dry tetrahydrofuran (230 mL) was added sodium hydride 
(1.02 g of a 60% dispersion in mineral oil, 25.4 mmol). After stirring at 20 °C for 20 min, 
ethyl-6-bromohexanoate (5.16 g, 23.1 mmol) was added and the mixture was heated at reflux 
for 16 h. After allowing to cool, the solvent was then evaporated and water (50 mL) added to 
the residue. The mixture was extracted with diethyl ether (2 x 30 mL) and the combined 
organic layers dried (MgSO4), filtered and evaporated. Column chromatography (1:9 ethyl 
acetate:40-60 °C petroleum ether) of the oily residue gave ester 1 (6.11 g, 74%) as a 
colourless oil; IR νmax 2935, 1732, 1369 cm-1; 1H NMR (CDCl3, 300 MHz) δ 4.04 (2H, q, 
J=7.1 Hz, CH2O), 3.02 (2H, t, J=7.6 Hz, CH2COOEt), 2.20 (2H, t, J=7.5 Hz, CHCH2), 1.79-
1.70 (2H, m, CH2CH2COOEt, 1.63-1.52 (2H, m, CHCH2CH2CH2), 1.38 (18H, s, C(CH3)3), 
1.34-1.25 (2H, m, CHCH2CH2), 1.17 (3H, t, J=7.1 Hz, CH2CH3); 13C NMR (CDCl3, 75 MHz) 
δ 173.5 (COOEt), 168.8 (COOC(CH3)3), 81.1 (C(CH3)3), 60.1 (CH2CH3), 53.8 (CH), 34.1 
(CH2COOEt), 28.7 (CHCH2), 28.3 (CH2CH2CH2COOEt), 27.8 (C(CH3)3), 26.8 (CHCH2CH2), 
24.6 (CH2CH2COOEt), 14.2 (CH3CH2); m/z (CI, %) 381 (M+H, 100), 269 (25), 247 (75), 201 
(13); HRMS (M+Na) calcd for C19H34O6 381.2253. Found: 381.2260. 
2-Carboxyoctanedioic acid 8-ethyl ester (2). To a stirred solution of 6-ethyl 1,1-bis(tert-
butyl) hexane-1,1,6-tricarboxylate (1) (6.09 g, 17.0 mmol) in dichloromethane (170 mL) was 
added trifluoroacetic acid (11.6 g, 102 mmol) and the solution stirred for 24 h. The volatile 
material was then evaporated to give the acid 2 (4.14 g, 99%) as a white crystalline solid, mp 
71-73 ˚C; IR νmax 2939, 2613, 1705 cm-1; 1H NMR (CDCl3, 300 MHz) δ 4.12 (2H, q, J=7.1 
Hz, CH2CH3), 3.42 (1H, t, J=7.4 Hz, CH), 2.30 (2H, t, J=7.4 Hz, CH2COOEt), 1.98-1.85 (2H, 
m, CH2CH2COOEt), 1.65-1.52 (2H, m, CHCH2), 1.43-1.25 (4H, m, CHCH2CH2, 
CHCH2CH2CH2), 1.18 (3H, t, J=7.1 Hz, CH2CH3); 13C NMR (CDCl3, 75 MHz) δ 174.6 
(COOH), 174.5 (COOEt), 60.7 (CH2CH3), 51.5 (CH), 34.2 (CH2COOEt), 28.6 
(CHCH2CH2CH2), 28.5 (CHCH2), 26.8 (CHCH2CH2), 24.5 (CH2CH2COOEt), 14.2 (CH2CH3); 
m/z (CI, %) 247 (M+H, 31), 201 (21), 185 (100), 157 (27). Anal. Calcd for C11H18O6 C, 53.65; 
H, 7.37. Found: C, 53.48; H, 7.41. 
tert-Butyl 3-oxo-3-(phenylamino)propanoate (5). Oxalyl chloride (11.7 g, 92.3 mmol) was 
added slowly to a stirred solution of 3-tert-butoxy-3-oxopropanoic acid (4.93 g, 30.8 mmol) 
in dichloromethane (300 mL) followed by DMF (10 drops). The mixture was warmed to 40 
˚C for 2 h then evaporated. The resulting red oil was dissolved in dichloromethane (300 mL), 
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and aniline (3.09 g, 33.9 mmol) added, giving a precipitate. DMAP (4.14 g, 33.9 mmol) was 
added and the mixture was then stirred at 20 °C for 2 h. The solvent was evaporated and the 
residue dissolved in ethyl acetate (50 mL). The organic layer was washed with 2 M 
hydrochloric acid (2 x 30 mL) followed by saturated aqueous sodium hydrogen carbonate (30 
mL), then dried (MgSO4) and filtered. The solvent was evaporated to leave a red oil which 
was purified by column chromatography (3:7 ethyl acetate:40-60 petroleum ether) to give 
ester 5 (6.92 g, 89%) as a white crystalline solid, mp 72-74 ˚C; IR νmax 3308, 3267, 1721, 
1556 cm-1; 1H NMR (CDCl3, 300 MHz) δ 9.35 (1H, s, NH), 7.55 (2H, dd, J=0.9, 8.5 Hz, 2,6-
aryl), 7.29 (2H, t, J=7.9 Hz, 3,5-aryl), 7.08 (1H, t, J=7.4 Hz, 4-aryl), 3.36 (2H, s, CH2), 1.48 
(9H, s, C(CH3)3); 13C NMR (CDCl3, 75 MHz) δ 168.9 (COOBut), 163.8 (CONH), 137.7 (1-
aryl), 128.9 (3,5-aryl), 124.4 (4-aryl), 120.1 (2,6-aryl), 82.9 (C(CH3)3), 42.9 (CH2), 28.0 
((CH3)3); m/z (CI, %) 235 (M+, 41), 179 (81), 162 (17), 119 (19), 93 (100). Anal. Calcd for 
C13H17NO3 C, 66.36; H, 7.28; N, 5.95. Found C, 66.35; H, 7.34; N, 5.98. 
1-tert-Butyl 8-ethyl-2-(phenylcarbamoyl)octanedioate (6). Sodium hydride (773 mg of a 60 
% dispersion in oil, 19.3 mmol) was added slowly to a stirred solution of tert-butyl 3-oxo-3-
(phenylamino)propanoate (5) (4.45 g, 17.57 mmol) in dry tetrahydrofuran (175 mL) at 0 °C. 
After stirring at 20 °C for 20 min, ethyl 6-bromohexanoate (3.92 g, 17.6 mmol) was added 
and the mixture heated at 70 ˚C for 18 h. After allowing to cool the solvent was evaporated. 
The residue was taken up in ethyl acetate (50 mL) and washed with 2 M hydrochloric acid (2 
x 20 mL) then with brine (20 mL), dried (MgSO4) and filtered. The residue was purified by 
column chromatography (1:9 ethyl acetate:40-60 °C petroleum ether) to give the ester 6 (4.94 
g, 74%) as pale yellow crystals, mp 65-66 ˚C; IR νmax 3307, 2944, 1726, 1656, 1554 cm-1; 1H 
NMR (CDCl3, 300 MHz) δ 8.75 (1H, s, NH), 7.54 (2H, d, J=8.3 Hz, 2,6-aryl), 7.32 (2H, t, 
J=7.9 Hz, 3,5-aryl), 7.10 (1H, t, J=7.4 Hz, 4-aryl), 4.11 (2H, q, J=7.1 Hz, CH2CH3), 3.24 (1H, 
t, J=7.3 Hz, CH), 2.28 (2H, t, J=7.4 Hz, CH2COO), 2.00-1.90 (2H, m, CHCH2), 1.68-1.57 
(2H, m, CH2CH2COO), 1.49 (9H, s, (CH3)3), 1.44-1.32 (4H, m, CH2CH2CH2COO, 
CHCH2CH2), 1.24 (3H, t, J=7.1 Hz, CH2CH3); 13C NMR (CDCl3, 75 MHz) δ 173.6 (COOEt), 
172.0 (CONH), 167.0 (COOBut), 137.8 (1-aryl), 129.0 (3,5-aryl), 124.3 (4-aryl), 119.9 (2,6-
aryl), 82.7 (C(CH3)3), 60.2 (CH2CH3), 54.4 (CH), 34.2 (CH2COO), 31.5 (CHCH2), 28.6 
(CH2CH2CH2CHOO), 28.0 (CH3)3), 26.9 (CHCH2CH2), 24.6 (CH2CH2COO), 14.2 (CH2CH3); 
m/z (EI, %)  377 (M+, 13), 322 (12), 258 (11), 179 (53), 161 (37), 93 (100). Anal. Calcd for 
C21H31NO5 C, 66.82; H, 8.28; N, 3.71. Found C, 66.72; H, 8.32; N, 3.69. 
tert-Butyl 8-(hydroxyamino)-8-oxo-2-(phenylcarbamoyl)octanoate (7). To a solution of 1-
tert-butyl 8-ethyl 2-(phenylcarbamoyl)octanedioate (6) (300 mg, 0.79 mmol) in 
tetrahydrofuran (8 mL) was added 50% aqueous hydroxylamine (0.53 mL, 7.95 mmol) and 1 
M potassium hydroxide in methanol (2.37 mL, 2.37 mmol) dropwise. The mixture was stirred 
 10 
at 20 °C for 1 h then acidified with 2 M hydrochloric acid. The solvent was evaporated to a 
volume of 5 mL then water (20 mL) added. The aqueous mixture was extracted with ethyl 
acetate (4 x 15 mL) and the combined yellow extracts dried over Na2SO4. Evaporation of the 
solvent gave a yellow oil which was purified by column chromatography (ethyl acetate) to 
give the hydroxamic acid 7 (84 mg, 29%) as a yellow oil; 1H NMR (CDCl3, 300 MHz) δ 9.02 
(1H, s, NH), 7.52 (2H, d, J=7.7 Hz, 2,6-aryl), 7.26 (2H, t, J=7.7 Hz, 3,5-aryl), 7.06 (1H, t, 
J=7.3 Hz, 4-aryl), 3.27 (1H, t, J=7.0 Hz, CH), 2.13-2.03 (2H, m, CH2CONHOH), 1.95-1.83 
(2H, m, CHCH2), 1.64-1.50 (2H, m, CH2CH3CONHOH), 1.44 (9H, s, C(CH3)3), 1.40-1.25 
(4H, m, CHCH2CH2, CHCH2CH2CH2); 13C NMR (CDCl3, 75 MHz) δ 171.7 (COOC(CH3)3), 
171.3 (CONHOH), 167.8 (CONHPh), 137.7 (1-aryl), 128.9 (3,5-aryl), 124.6 (4-aryl), 120.3 
(2,6-aryl), 82.7 (C(CH3)3), 54.2 (CH), 32.5 (CH2CONHOH), 30.5 (CHCH2), 28.3 
(CHCH2CH2CH2), 28.0 (C(CH3)3), 26.6 (CH2CH2CONHOH), 25.0 (CHCH2CH2); m/z (CI, %) 
387 (M+Na, 100), 365 (M+H, 45), 328 (22), 309 (35). HRMS calcd for C19H28N2O5 (M+H) 
365.2071. Found: 365.2079. 
8-(Hydroxyamino)-8-oxo-2-(phenylcarbamoyl)octanoic acid (8). To a solution of tert-butyl 
8-(hydroxyamino)-8-oxo-2-(phenylcarbamoyl)octanoate (7) (170 mg, 0.47 mmol) in 
dichloromethane (2 mL) was added trifluoroacetic acid (2 mL) and the mixture stirred for 30 
min. Evaporation of the solvent gave a pale yellow solid which was washed with cold diethyl 
ether then with dichloromethane to give the hydroxamic acid 8 (116 mg, 80%) as a white 
solid, mp 150-152 ˚C; IR νmax 2931, 2856, 1733, 1597, 1547 cm-1; 1H NMR (CD3OD, 300 
MHz) δ 7.55 (2H, d, J=7.6 Hz, 2,6-aryl), 7.30 (2H, t, J=7.3 Hz, 3,5-aryl), 7.09 (1H, t, J=7.1 
Hz, 4-aryl), 3.44 (1H, t, J=7.1 Hz, CH), 2.07 (2H, t, J=6.8 Hz, CH2CONH), 2.02-1.86 (2H, m, 
CHCH2), 1.76-1.58 (2H, m, CH2CH2CONH), 1.53-1.30 (4H, m, CHCH2CH2, 
CHCH2CH2CH2); 13C NMR (CD3OD, 75 MHz) δ 173.4 (COOH), 173.0 (CONHPh), 170.4 
(CONHOH), 139.6 (1-aryl), 129.9 (3,5-aryl), 125.5 (4-aryl), 121.4 (2,6-aryl), 54.4 (CH), 33.7 
(CH2CONH), 30.2 (CHCH2), 29.9 (CHCH2CH2CH2), 28.1 (CH2CH2CONH), 26.3 
(CHCH2CH2); m/z (CI, %) 331 (M+Na, 100), 309 (M+H, 83). Anal. Calcd for C15H20N2O5 C, 
58.43; H, 6.54; N, 9.09. Found C, 58.16; H, 6.51; N, 8.75. 
8-Ethoxy-8-oxo-2-(phenylcarbamoyl)octanoic acid (9). Trifluoroacetic acid (9 mL) was 
added to a solution of 1-tert-butyl-8-ethyl-2-(phenylcarbamoyl)octanedioate (6) (1.33 g, 3.52 
mmol) in dichloromethane (9 mL) and the solution stirred for 6 h. The solvent was evaporated 
and the residue washed with a 1:1 diethyl ether:40-60 °C petroleum ether to give the acid 9 
(0.91 g, 80%) as a white powder, mp 108-110 ˚C; IR νmax 3426, 3340, 2933, 1730, 1600 cm-1; 
1H NMR (CDCl3, 300 MHz) δ 10.17 (1H, br s, OH), 9.05 (1H, s, NH), 7.50 (2H, d, J=7.8 Hz, 
2,6-aryl), 7.30 (2H, t, J=7.7 Hz, 3,5-aryl), 7.14 (1H, t, J=7.3 Hz, 4-aryl), 4.12 (2H, q, J=7.1 
Hz, CH2CH3), 3.47 (1H, t, J=6.2 Hz, CH), 2.29 (2H, t, J=7.3 Hz, CH2COO), 2.06-1.95 (2H, 
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m, CHCH2), 1.68-1.53 (2H, m, CH2CH2COO), 1.48-1.30 (4H, m, CH2CH2CH2COO, 
CHCH2CH2), 1.24 (3H, t, J=7.1 Hz, CH3); 13C NMR (CDCl3, 75 MHz) δ 175.1 (COOH), 
174.6 (COOEt), 169.1 (CONH), 136.7 (1-aryl), 129.1 (3,5-aryl), 125.5 (4-aryl), 120.8 (2,6-
aryl), 60.9 (CH2CH3), 52.2 (CH), 34.1 (CH2COO), 31.1 (CHCH2), 28.3 (CH2CH2CH2COO), 
26.5 (CHCH2CH2), 24.4 (CH2CH2COO), 14.1 (CH3); m/z (EI, %) 321 (M+, 8), 277 (43), 232 
(54), 179 (36), 135 (97), 93 (100). Anal. Calcd for C17H23NO5 C, 63.53; H, 7.21; N, 4.36. 
Found C, 63.08; H, 7.18; N, 3.92. 
Ethyl 7-(hydroxymethyl)-8-oxo-8-(phenylamino)octanoate (10). To a stirred solution of 8-
ethoxy-8-oxo-2-(phenylcarbamoyl)octanoic acid (9) (300 mg, 0.94 mmol) in dry 
tetrahydrofuran (3.0 mL) at 0 ˚C was added triethylamine (114 mg, 1.13 mmol) and ethyl 
chloroformate (152 mg, 1.40 mmol). The mixture was stirred at 0 ˚C for 30 min then filtered. 
The solid was washed with tetrahydrofuran (2 x 3 mL) and the combined filtrate was cooled 
to 10 ˚C. Sodium borohydride (107 mg, 2.82 mmol) was added in one portion, followed by 
dropwise addition of methanol (0.6 mL) over a period of 1 h. After stirring for a further 30 
min the reaction was quenched by dropwise addition of 2 M hydrochloric acid, then extracted 
with dichloromethane (2 x 10 mL). The combined organic layers were dried (MgSO4), filtered 
and evaporated. The residue was purified by column chromatography (3:2 ethyl acetate:40-60 
°C petroleum ether) to give ester 10 (222 mg, 77%) as a crystalline white solid, mp 132-134 
˚C; IR νmax 2935, 2669, 1684, 1408 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.73 (1H, s, NH), 
7.53 (2H, d, J=7.7 Hz, 2,6-aryl), 7.23 (2H, t, J=7.9 Hz, 3,5-aryl), 7.04 (1H, t, J= 7.4 Hz, 4-
aryl), 4.08 (2H, q, J=7.1 Hz, CH2CH3), 3.95 (1H, br s, OH), 3.73 (1H, t, J=9.0 Hz, CH2OH), 
3.73-3.53 (1H, m, CH2OH), 2.45 (1H, m, CH), 2.22 (2H, t, J=7.4 Hz, CH2COO), 1.56 (3H, 
CHCHH, CH2CH2COO), 1.40-1.18 (8H, m, CHCHH, CH2CH2CH2COO, CHCH2CH2, CH3); 
13C NMR (CDCl3, 75 MHz) δ 174.1 (COOEt), 174.1 (CONH), 138.1 (1-aryl), 128.8 (3,5-
aryl), 124.2 (4-aryl), 120.2 (2,6-aryl), 63.5 (CH2OH), 60.4 (CH2CH3), 49.7 (CH), 34.2 
(CH2COO), 29.0 (CH2CH2CH2COO), 28.7 (CHCH2), 26.9 (CHCH2CH2), 24.6 
(CH2CH2COO), 14.2 (CH3); m/z (CI, %) 308 (M+H, 100), 262 (53), 197 (63), 169 (51). Anal. 
Calcd for C17H25NO4 C, 66.43; H, 8.20; N, 4.56. Found C, 66.49; H, 8.34; N, 4.65. 
N8-hydroxy-2-(hydroxymethyl)-N1-phenyloctanediamide (11). To a stirred solution of 
ethyl 7-(hydroxymethyl)-8-oxo-8-(phenylamino)octanoate (10) (600 mg, 1.95 mmol) in 
tetrahydrofuran (20 mL) was added 50% aqueous hydroxylamine (0.64 mL, 9.76 mmol) and 1 
M potassium hydroxide in methanol (3.9 mL, 3.9 mmol) and the resultant solution stirred for 
1.5 h. Methanol was evaporated from the yellow solution then 0.5M hydrochloric acid (10 
mL) added. The hydroxamic acid 11 (70 mg, 12%) crystallised from the aqueous solution as 
cream solid, mp 150-151 ˚C; IR νmax 3398, 3291, 3185, 2920, 1626 cm-1; 1H NMR ((CD3)2SO, 
300 MHz) δ 10.30 (1H, s, NH), 9.83 (1H, s, NHOH), 8.62 (1H, s, NH), 7.62 (2H, d, J=7.8 
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Hz, 2,6-aryl), 7.27 (2H, t, J=7.9 Hz, 3,5-aryl), 7.00 (1H, t, J=7.4 Hz, 4-aryl), 4.71 (1H, t, 
J=5.0 Hz, OH), 3.64-3.55 (1H, m, CHHOH), 3.45 (1H, td, J=5.1, 10.2 Hz, CHHOH), 2.57-
2.45 (1H, m, CH), 1.90 (2H, t, J=7.3 Hz, CH2CONH), 1.54-1.35 (4H, m, CH2CH2CONH, 
CHCH2), 1.30-1.17 (4H, m, CHCH2CH2CH2, CHCH2CH2); 13C NMR ((CD3)2SO, 75 MHz) δ 
173.0 (PhNHCO), 169.0 (CONHOH), 139.3 (1-aryl), 128.5 (3,5-aryl), 122.9 (4-aryl), 119.1 
(2,6-aryl), 62.9 (CH2OH), 49.8 (CH), 32.2 (CH2CONH), 28.7 (CHCH2CH2CH2), 28.6 
(CHCH2), 26.6 (CHCH2CH2), 25.0 (CH2CH2CONH); m/z (CI, %) (M+Na, 100), 285 (17), 276 
(15), 242 (13), 217 (13). Anal. Calcd for C15H22N2O4 C, 61.21; H, 7.53; N, 9.52. Found: C, 
60.71; H, 7.49; N, 9.39. 
Ethyl 8-(2-(tert-butoxycarbonylamino)phenylamino)-8-oxo-7-(phenylcarbamoyl)-
octanoate (12). To a stirred solution of 8-ethoxy-8-oxo-2-(phenylcarbamoyl)octanoic acid (9) 
(1.0 g, 3.11 mmol) in DMF (30 mL) was added tert-butyl 2-aminophenylcarbamate (648 mg, 
3.11 mmol), triethylamine (692 mg, 6.84 mmol), EDC.HCl (657 mg, 3.42 mmol) and HOBt 
(462 mg, 3.42 mmol). The mixture was stirred for 18 h then evaporated and water (50 mL) 
added to the residue. The mixture was extracted with ethyl acetate (2 x 25 mL) and the 
combined organic layers were washed with water (15 mL), saturated aqueous ammonium 
chloride (15 mL) and lastly with saturated aqueous sodium hydrogen carbonate (15 mL). The 
organic layer was dried (MgSO4), filtered and evaporated to give a yellow oil which was 
purified by column chromatography (1:2 40-60 °C petroleum ether: ethyl acetate) to give 
amide 12 (1.05 g, 66%) as a white solid, used without further purification. 
Ethyl 7-(1H-benzo[d]imidazol-2-yl)-8-oxo-8-(phenylamino)octanoate (13). To a solution 
of ethyl 8-(2-(tert-butoxycarbonylamino)phenylamino)-8-oxo-7-(phenylcarbamoyl)octanoate 
(12) (0.88 g, 1.72 mmol) in dichloromethane (9 mL) was added trifluoroacetic acid (9 mL). 
The solution was heated at reflux for 2 h. The solvent was evaporated and the residue 
recrystallised from a mixture of ethyl acetate and 40-60 °C petroleum ether to give ester 13 
(505 mg, 75%) as a white crystalline solid, mp 211-212 ˚C; IR νmax 3284, 2926, 1734, 1666 
cm-1; 1H NMR (CDCl3, 300 MHz) δ 11.95 (1H, s, NH), 11.47 (1H, s, NH), 7.66 (3H, m, 2,6-
aryl, 7-benzimidazolyl), 7.48 (1H, m, 4-benzimidazolyl), 7.25 (4H, m, 3,5-aryl, 5,6-
benzimidazolyl), 7.10 (1H, t, J=7.4 Hz, 4-aryl), 4.65 (1H, t, J=7.7 Hz, CH), 4.02 (2H, q, 
J=7.1 Hz, CH2CH3), 2.32 (1H, m, CHCHH), 2.15 (1H, m, CHCHH), 1.99 (2H, t, J=7.5 Hz, 
CH2COO), 1.36 (4H, m, CHCH2CH2, CH2CH2COO), 1.19 (5H, m, CH2CH2CH2COO, 
CH2CH3); 13C NMR (CDCl3, 75 MHz) δ 173.5 (COO), 170.8 (NHCO), 153.3 (2-
benzimidazolyl), 142.1 (7a-benzimidazolyl), 138.2 (1-aryl), 134.2 (3a-benzimidazolyl), 129.0 
(3,5-aryl), 124.7 (4-aryl), 123.2 (7-benzimidazolyl), 122.4 (4-benzimidazolyl), 120.4 (2,6-
aryl), 118.3 (6-benzimidazolyl), 111.7 (5-benzimidazolyl), 60.1 (CH2CH3), 48.3 (CH), 34.0 
(CH2COO), 33.6 (CHCH2), 28.5 (CH2CH2CH2COO), 27.2 (CHCH2CH2), 24.5 
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(CH2CH2COO), 14.2 (CH2CH3); m/z (CI, %) 394 (M+H, 100), 293 (58), 274 (23). Anal. 
Calcd for C23H27N3O3 C, 70.21; H, 6.92; N, 10.68. Found C, 70.17; H, 7.01; N, 10.79. 
tert-Butyl 2-(8-ethoxy-1,8-dioxo-1-(phenylamino)octan-2-yl)-1H-benzo[d]imidazole-1-
carboxylate (14). Di-tert-butyl dicarbonate (403 mg, 1.85 mmol) was added to a stirred 
solution of ethyl 7-(1H-benzo[d]imidazol-2-yl)-8-oxo-8-(phenylamino)octanoate (13) (484 
mg, 1.23 mmol) in tetrahydrofuran (12 mL). The solution was stirred at 20 °C for 7 d. 
Evaporation gave a residue was purified by column chromatography (1:4 ethyl acetate:40-60 
°C petroleum ether) to give recovered 13 (220 mg, 45%) and ester 14 (210 mg, 35%) as a 
colourless oil; IR νmax 3319, 2936, 1732, 1600 cm-1; 1H NMR (CDCl3, 300 MHz) δ 9.46 (1H, 
s, NH), 7.94-7.89 (1H, m, 7-benzimidazolyl), 7.82-7.77 (1H, m, 4-benzimidazolyl), 7.57 (2H, 
d, J=8.5 Hz, 2,6-aryl), 7.39-7.35 (2H, m, 5,6-benzimidazolyl), 7.28 (2H, t, J=7.5 Hz, 3,5-
aryl), 7.04 (1H, t, J=7.5 Hz, 4-aryl), 4.82 (1H, t, J=7.2 Hz, CH), 4.07 (2H, q, J=7.1 Hz, 
CH2CH3), 2.38-2.25 (4H, m, CHCH2, CH2COO), 1.72 (9H, s, C(CH3)3), 1.69-1.57 (2H, m, 
CH2CH2COO), 1.55-1.35 (4H, m, CHCH2CH2, CHCH2CH2CH3), 1.21 (3H, t, J=7.1 Hz, 
CH2CH3); 13C NMR (CDCl3, 75 MHz) δ 173.7 (COOEt), 168.1 (CONH), 154.1 (COOBut), 
149.2 (2-benzimidazolyl), 141.7 (7a-benzimidazolyl), 138.2 (1-aryl), 132.6 (3a-
benzimidazolyl), 128.9 (3,5-aryl), 125.0 (6-benzimidazolyl), 124.5 (5-benzimidazolyl), 124.1 
(4-aryl), 119.9 (7-benzimidazolyl), 119.7 (2,6-aryl), 115.2 (4-benzimidazolyl), 86.7 
(C(CH3)3), 60.2 (CH2CH3), 48.1 (CH), 34.2 (CH2COO), 33.5 (CHCH2), 28.9 
(CHCH2CH2CH2), 28.1 (C(CH3)3), 27.0 (CHCH2CH2), 24.7 (CH2CH2COO), 14.3 (CH2CH3); 
m/z (CI, %) 516 (M+Na, 49), 494 (M+H, 92), 394 (28), 335 (100), 276 (19). HRMS (M+H) 
calcd for C28H35N3O5 494.2655. Found: 494.2650. 
2-(1H-Benzo[d]imidazol-2-yl)-N8-hydroxy-N1-phenyloctanediamide (15). To a stirred 
solution of tert-butyl 2-(8-ethoxy-1,8-dioxo-1-(phenylamino)octan-2-yl)-1H-
benzo[d]imidazole-1-carboxylate (14) (210 mg, 0.43 mmol) in tetrahydrofuran (4 mL) was 
added 50% aqueous hydroxylamine (0.28 mL, 4.25 mmol) followed by dropwise addition of 
1 M potassium hydroxide in methanol (1.29 mL). The pale yellow solution was stirred for 6 h 
then evaporated. Water (10 mL) was added to the residue followed by saturated aqueous 
ammonium chloride (10 mL) and the precipitate collected by filtration. The solid was 
recrystallised from ethanol to give the hydroxamic acid 15 (81 mg, 50%) as a white 
crystalline solid, mp 184-185 ˚C; IR νmax 3261, 3093, 2924, 1637 cm-1; 1H NMR (CD3OD, 300 
MHz) δ 7.75-7.45 (4H, m, 2,6-aryl, 4,7-benzimidazolyl), 7.27 (2H, t, J=7.5 Hz, 3,5-aryl), 
7.24-7.18 (2H, m, 5,6-benzimidazolyl), 7.06 (1H, t, J=7.5 Hz, 4-aryl), 4.20-4.00 (1H, m, CH), 
2.28-1.97 (4H, m, CHCH2, CH2CONH), 1.68-1.50 (2H, m, CH2CH2CONH), 1.48-1.30 (4H, 
m, CHCH2CH2, CHCH2CH2CH2); 13C NMR ((CD3)2SO, 125 MHz) δ 169.3 (PhNHCO), 169.3 
(CONHOH), 152.7 (2-benzimidazolyl), 142.7 (benzimidazolyl), 138.9 (1-aryl), 134.6 
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(benzimidazolyl), 128.7 (3,5-aryl), 123.5 (4-aryl), 121.8 (benzimidazolyl), 121.0 
(benzimidazolyl), 119.3 (benzimidazolyl), 118.3 (benzimidazolyl), 111.3 (benzimidazolyl), 
47.8 (CH), 32.2 (CH2CONHOH), 31.1 (CHCH2), 28.4 (CHCH2CH2CH2), 26.8 (CHCH2CH2), 
25.0 (CH2CH2CONHOH). Anal. Calcd for C21H24N4O3.0.5H2O C, 64.75; H, 6.47; N, 14.39. 
Found C, 65.18; H, 6.36; N, 14.13. 
tert-Butyl 3-(2-aminophenylamino)-3-oxopropanoate (16). To a solution of 3-tert-butoxy-
3-oxopropanoic acid (200 mg, 1.25 mmol) and 1,2-phenylenediamine (135 mg, 1.25 mmol) in 
acetonitrile (5 mL) was added a solution of DCC (283 mg, 1.37 mmol) in acetonitrile (2 mL) 
and the reaction stirred for 20 min. The white suspension was filtered and the filtrate 
evaporated to leave a dark yellow oil which was purified by column chromatography (1:1 
ethyl acetate:40-60 °C petroleum ether) followed by recrystallisation from a mixture of ethyl 
acetate and 40-60 °C petroleum ether to give amide 16 (155 mg, 50%) as a white crystalline 
solid, mp 122-123 ˚C; IR νmax 3428, 3318, 1718, 1655 cm-1; 1H NMR (CDCl3, 300 MHz) δ 
8.89 (1H, s, NH), 7.29-7.25 (1H, m, 3-aryl), 7.09-7.02 (1H, m, 5-aryl), 6.84-6.77 (2H, m, 4,6-
aryl), 3.59 (2H, br s, NH2), 3.40 (2H, s, CH2), 1.50 (9H, s, (CH3)3); 13C NMR (CDCl3, 75 
MHz) δ 169.1 (COOBut), 164.2 (CONH), 140.6 (2-aryl), 127.2 (4-aryl), 125.3 (6-aryl), 123.8 
(1-aryl), 119.3 (5-aryl), 117.7 (3-aryl), 83.1 (C(CH3)3), 42.0 (CH2), 28.0 ((CH3)3). Anal. Calcd 
for C13H18N2O3 C, 62.38; H, 7.25; N, 11.19. Found C, 62.29; H, 7.28; N, 11.13. 
tert-Butyl 2-(1H-benzo[d]imidazol-2-yl)acetate (17). tert-Butyl 3-(2-aminophenylamino)-3-
oxopropanoate (16) (70 mg, 0.28 mmol) was dissolved in acetic acid (0.15 mL) and the 
solution heated to 90 ˚C for 1 h. After allowing to cool the solvent was evaporated and the 
residue recrystallised from a mixture of ethyl acetate and 40-60 °C petroleum ether to give 
ester 17 (62 mg, 96%) as a white crystalline solid, mp 158-161 ˚C; IR νmax 2984, 1722, 1435 
cm-1; 1H NMR (CDCl3, 300 MHz) δ 10.0 (1H, br s, NH), 7.56 (2H, dd, J=3.2, 6.0 Hz, 4,7-
benzimidazolyl), 7.22 (2H, dd, J=3.2, 6.0 Hz, 5,6-benzimidazolyl), 3.99 (2H, s, CH2), 1.46 
(9H, s, (CH3)3); 13C NMR (CDCl3, 75 MHz) δ 169.0 (COOBut), 147.8 (2-benzimidazolyl), 
138.3 (3a,7a-benzimidazolyl), 122.5 (4,7-benzimidazolyl), 115.0 (5,6-benzimidazolyl), 82.7 
(C(CH3)3), 35.7 (CH2), 28.0 ((CH3)3). Anal. Calcd for C13H16N2O2 C, 67.22; H, 6.49; N, 12.06. 
Found C, 67.10; H, 6.97; N, 11.97. 
tert-Butyl 2-(2-tert-butoxy-2-oxoethyl)-1H-benzo[d]imidazole-1-carboxylate (18). To a 
stirred solution of tert-butyl 2-(1H-benzo[d]imidazol-2-yl)acetate (17) (3.37 g, 14.5 mmol) in 
tetrahydrofuran (33 mL) was added di-tert-butyl dicarbonate (3.80 g, 17.4 mmol) and the 
solution stirred at 20 °C for 3 d. Evaporation gave a residue that was subjected to column 
chromatography (1:4 ethyl acetate:40-60 °C petroleum ether) to give ester 18 (4.68 g, 97%) as 
a colourless viscous oil which solidified on standing to a white solid, mp 82-83 ˚C; IR νmax 
2979, 1750, 1729 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.93-7.87 (1H, m, 7-benzimidazolyl), 
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7.74-7.67 (1H, m, 4-benzimidazolyl), 7.38-7.28 (2H, m, 5,6-benzimidazolyl), 4.19 (2H, s, 
CH2), 1.68 (9H, s, (CH3)3), 1.43 (9H, s, (CH3)3); 13C NMR (CDCl3, 300 MHz) δ 167.9 
(NCOO), 149.7 (CH2COO), 148.9 (2-benzimidazolyl), 142.1 (3a-benzimidazolyl), 132.9 (7a-
benzimidazolyl), 124.6 (7-benzimidazolyl), 124.1 (4-benzimidazolyl), 119.8 (5-
benzimidazolyl), 114.9 (6-benzimidazolyl), 85.7 (C(CH3)3), 81.7 (C(CH3)3), 39.1 (CH2), 28.0 
((CH3)3), 28.0 ((CH3)3). Anal. Calcd for C18H24N2O3 C, 65.04; H, 7.28; N, 8.43. Found C, 
65.02; H, 7.26; N, 8.30. 
1-tert-Butyl, 8-ethyl 2-(1-(tert-butoxycarbonyl)-1H-benzo[d]imidazol-2-yl)octanedioate 
(19). Sodium hydride (337 mg of a 60% dispersion in mineral oil, 14.0 mmol) was added to a 
stirred solution of tert-butyl 2-(2-tert-butoxy-2-oxoethyl)-1H-benzo[d]imidazole-1-
carboxylate (18) (4.24 g, 12.8 mmol) in dry tetrahydrofuran (130 mL). The suspension was 
stirred for a further 30 min, then ethyl 6-bromohexanoate (3.13 g, 14.0 mmol) added and the 
mixture stirred at 60 ˚C for 18 h. A further portion of sodium hydride (337 mg, 14.0 mmol) 
was then added (with effervescence) and stirring continued at 60 ˚C for 4 h. After allowing to 
cool the solvent was evaporated and ethyl acetate (80 mL) added. The suspension was washed 
with saturated aqueous ammonium chloride (40 mL), dried (MgSO4), filtered and evaporated 
to give a brown oil which was purified by column chromatography (15:85 ethyl acetate:40-60 
°C petroleum ether) to give ester 19 (2.01 g, 33%) as a yellow oil; IR νmax 2978, 1731, 1453 
cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.88-7.83 (1H, m, 7-benzimidazolyl), 7.73-7.68 (1H, m, 
4-benzimidazolyl), 7.28-7.23 (2H, m, 5,6-benzimidazolyl), 4.39 (1H, dd, J=6.1, 8.3 Hz, CH), 
4.05 (2H, q, J=7.1 Hz, CH2CH3), 2.36-2.09 (4H, m, CHCH2, CH2COO), 1.66 (9H, m, (CH3)3), 
1.65-1.57 (2H, m, CH2CH2COO), 1.55-1.43 (4H, m, CHCH2CH2, CHCH3CH3CH2), 1.40 (9H, 
m, (CH3)3), 1.18 (3H, t, J=7.1 Hz, CH2CH3); 13C NMR (CDCl3, 75 MHz) δ 173.6 (COOEt), 
170.5 (CHCOOBut), 153.5 (NCOO), 149.1 (2-benzimidazolyl), 142.1 (7a-benzimidazolyl), 
132.8 (3a-benzimidazolyl), 124.4 (7-benzimidazolyl), 124.0 (4a-benzimidazolyl), 120.0 (5-
benzimidazolyl), 115.0 (6-benzimidazolyl), 85.5 (C(CH3)3), 81.2 (C(CH3)3), 60.0 (CH2CH3), 
48.2 (CH), 34.2, (CH2COO), 29.8 (CHCH2), 28.9 (CHCH2CH2CH2), 28.1 ((CH3)3), 27.8 
((CH3)3), 27.5 (CHCH2CH2), 24.7 (CH2CH2COO), 14.2 (CH2CH3); m/z (EI, %) 497 (M+H, 
34), 441 (33), 397 (57), 297 (100), 251 (86). HRMS (M+H) calcd for C26H38N2O6 497.2628. 
Found: 497.2620. 
tert-Butyl 2-(1H-benzo[d]imidazol-2-yl)-8-(hydroxyamino)-8-oxooctanoate (20). To a 
stirred solution of 1-tert-butyl 8-ethyl 2-(1-(tert-butoxycarbonyl)-1H-benzo[d]imidazol-2-
yl)octanedioate (19) (1.0 g, 2.11 mmol) in tetrahydrofuran (20 mL) was added 50% aqueous 
hydroxylamine (1.39 mL, 21.1 mmol) followed by dropwise addition of 1 M potassium 
hydroxide in methanol (6.33 mL). The mixture was stirred for 30 min then the solvent was 
evaporated. Water (15 mL) was added to the oily residue and the mixture neutralised with 1M 
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hydrochloric acid. On cooling, the precipitate was collected by filtration, air-dried and 
recrystallised from aqueous ethanol to give the hydroxamic acid 20 (508 mg, 67%) as a white 
crystalline solid, mp 110-115 ˚C; IR νmax 3341, 2934, 1704, 1650 cm-1; 1H NMR ((CD3)2SO, 
300 MHz) δ 12.31 (1H, br s, OH), 10.32 (1H, br s, NH), 8.65 (1H, br s, NH), 7.54 (1H, d, 
J=7.6 Hz, 7-benzimidazolyl), 7.44 (1H, d, J=7.0 Hz, 4-benzimidazolyl), 7.19-7.08 (2H, m, 
5,6-benzimidazolyl), 3.80 (1H, t, J=7.7 Hz, CH), 2.06-1.97 (2H, m, CHCH2), 1.90 (2H, t, 
J=7.3 Hz, CH2CONH), 1.52-1.43 (2H, m, CH2CH2CONH), 1.37 (9H, s, C(CH3)3), 1.33-1.24 
(4H, m, CHCH2CH2, CHCH2CH2CH2); 13C NMR ((CD3)2SO, 75 MHz) δ 170.2 (COO), 169.0 
(CONH), 151.7 (2-benzimidazolyl), 142.8 (7a-benzimidazolyl), 134.4 (3a-benzimidazolyl), 
121.8 (7-benzimidazolyl), 120.9 (4-benzimidazolyl), 118.4 (5-benzimidazolyl), 111.1 (6-
benzimidazolyl), 80.8 (C(CH3)3), 46.8 (CH), 32.1 (CH2CONH), 30.5 (CHCH2), 28.2 
(CHCH2CH2CH2), 27.6 (C(CH3)3), 26.5 (CH2CH2CONH), 24.9 (CHCH2CH2); m/z (EI, %) 384 
(M+Na, 100), 362 (54), 329 (79), 306 (36), 176 (99), 154 (99). HRMS (M+Na) calcd for 
C19H27N3O4 384.1899. Found: 384.1906. 
Ethyl 7-(1H-benzo[d]imidazol-2-yl)heptanoate (21). A solution of oxononane-2,9-dione 
(3.0 g, 19.2 mmol) in tetrahydrofuran (15 mL) was added dropwise to a stirred solution of 
1,2-phenylenediamine (2.08 g, 19.2 mmol) in tetrahydrofuran (30 mL) and the brown solution 
stirred for 45 min. Evaporation gave a residue which was dissolved in a solution of 4% by 
volume of concentrated sulfuric acid in ethanol (190 mL), previously prepared by slow 
addition of sulfuric acid to cold ethanol (CAUTION!). The orange solution was heated at 90 
˚C for 16 h then allowed to cool and quenched with saturated aqueous sodium hydrogen 
carbonate. The mixture was evaporated and water (20 mL) was added. This mixture was 
extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were dried 
(MgSO4), filtered and evaporated to give a brown oil which was purified by column 
chromatography (1:4 ethyl acetate:40-60 °C petroleum ether) to give an cream solid. 
Recrystallisation from diethyl ether afforded the ester 21 (1.52 g, 29%) as white needles, mp 
95-97 ˚C; IR νmax 2934, 1720, 1175, 1026 cm-1; 1H NMR (CDCl3, 300 MHz) δ 10.78 (1H, br s, 
NH), 7.54 (2H, dd, J=3.2, 6.0 Hz, 4,7-benzimidazolyl), 7.20 (2H, dd, J=3.2, 6.0 Hz, 5,6-
benzimidazolyl), 4.10 (2H, q, J=7.1 Hz, CH2CH3), 2.93 (2H, t, J=7.6 Hz, NCCH2), 2.21 (2H, 
t, J=7.4 Hz, CH2COO), 1.89-1.77 (2H, m, CH2CH2COO), 1.58-1.47 (2H, m, NCCH2CH2), 
1.39-1.19 (7H, m, NCCH2CH2CH2, CH2CH2CH2COO, CH3); 13C NMR (CDCl3, 75 MHz) δ 
174.0 (COO), 155.5 (2-benzimidazolyl), 138.6 (3a,7a-benzimidazolyl), 122.0 (4,7-
benzimidazolyl), 114.6 (5,6-benzimidazolyl), 60.3 (CH2CH3), 34.2 (CH2COO), 29.2 
(NCCH2), 28.8 (NCCH2CH2), 28.6 (CH2CH2CH2COO), 28.1 (NCCH2CH2CH2), 24.7 
(CH2CH2COO), 14.2 (CH3); m/z (CI, %) 275 (M+H, 100), 229 (6), 187 (4). Anal. Calcd for 
C16H22N2O2 C, 70.04; H, 8.08; N, 10.21. Found C, 69.87; H, 8.07; N, 10.12. 
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7-(1H-Benzo[d]imidazol-2-yl)-N-hydroxyheptanamide (22). To a stirred solution of ethyl 
7-(1H-benzo[d]imidazol-2-yl)heptanoate (21) (1.20 g, 4.37 mmol) in tetrahydrofuran (40 mL) 
was added 50% aqueous hydroxylamine (2.89 mL, 43.7 mmol) followed by slow addition of  
1 M potassium hydroxide in methanol (6.56 mL). The mixture was stirred at 20 °C for 2 h 
then evaporated. To the yellow residue was added water (60 mL) then the solution was 
acidified with 2M hydrochloric acid to give a white precipitate. After filtering, the product 
was washed with water, methanol and lastly with diethyl ether to give the hydroxamic acid 22 
(696 mg, 61%) as a white solid, mp 226-227 ˚C; IR νmax 3284, 2930, 2324, 1642 cm-1; 1H 
NMR ((CD3)2SO, 300 MHz) δ 10.33 (1H, s, NH), 8.67 (1H, s, NH), 7.51-7.30 (2H, m, 4,7-
benzimidazolyl), 7.13-7.05 (2H, m, 5,6-benzimidazolyl), 2.77 (2H, t, J=7.5 Hz, NNCCH2), 
1.92 (2H, t, J=7.3 Hz, CH2CO), 1.78-1.68 (2H, m, NNCCH2CH2), 1.54-1.42 (2H, m, 
CH2CH2CO), 1.38-1.23 (4H, m, CH2CH2CH2CH2CO, CH2CH2CH2CO); 13C NMR ((CD3)2SO, 
75 MHz) δ 174.2 (CO), 160.2 (2-benzimidazolyl), 148.4 (7a-benzimidazolyl), 139.4 (3a-
benzimidazolyl), 126.4 (7-benzimidazolyl), 125.9 (4-benzimidazolyl), 123.1 (6-
benzimidazolyl), 115.8 (5-benzimidazolyl), 37.3 (NNCCH2), 33.6 (CH2CO), 33.5 
(NNCCH2CH2), 33.4 (CH2CH2CH2CO), 32.5 (CH2CH2CH2CH2CO), 30.1 (CH2CH2CO); m/z 
(CI, %) 262 (M+H, 100), 242 (57), 201 (9). Anal. Calcd for C14H19N3O2 C, 64.35; H, 7.33; N, 
16.08. Found C, 64.36; H, 7.51; N, 15.89. 
6-Ethyl 1,1-bis(2,4,6-trichlorophenyl)hexane-1,1,6-tricarboxylate (23). A mixture of 2-
carboxyoctanedioic acid 8-ethyl ester (2) (1.34 g, 5.44 mmol) and 2,4,6-trichlorophenol (2.15 
g, 10.9 mmol) in phosphorus oxychloride (2.17 g, 14.4 mmol) was heated to 100 ˚C for 5 h. 
After allowing to cool, water (10 mL) was added. The mixture was extracted with ethyl 
acetate (2 x 10 mL) and the combined organic layers were washed with saturated aqueous 
sodium hydrogen carbonate (10 mL) and then with brine (10 mL). The organic layer was 
dried (MgSO4), filtered and the solvent evaporated to give a brown oil which was purified by 
column chromatography (5:95 ethyl acetate:40-60 °C petroleum ether) to give ester 23 as a 
colourless oil (1.61 g, 49%); IR νmax 2937, 1769, 1731, 1566 cm-1; 1H NMR (CDCl3, 300 
MHz) δ 7.44-7.37 (4H, m, 3,5-aryl), 4.13 (2H, q, J=7.1 Hz, CH2CH3), 4.05 (1H, t, J=7.4 Hz, 
COCHCO), 2.38-2.24 (4H, m, CHCH2, CH2CO2Et), 1.77-1.58 (4H, m, CH2CH2CO2Et, 
CHCH2CH2), 1.57-1.40 (2H, m, CHCH2CH2CH2), 1.25 (3H, t, J=7.1 Hz, CH2CH3); 13C NMR 
(CDCl3, 75 MHz) δ 173.5 (COOEt), 164.6 (COOAr), 142.4 (1-Ar), 132.6 (4-Ar), 129.5 (Ar) 
128.8 (Ar), 60.3 (CH2CH3), 50.7 (CH), 34.1 (CH2COOEt), 29.2 (CHCH2), 28.6 
(CH2CH2CH2COOEt), 27.0 (CHCH2CH2), 24.6 (CH2CH2COOEt), 14.1 (CH3CH2); m/z (CI, 
%) 626 (18), 211 (26), 176 (100). HRMS calcd for C23H20Cl6O6 (M+Na) 624.9289, found 
624.9275.                            
Ethyl 6-(2-(diethylamino)-4-hydroxy-6-oxo-1-phenyl-1,6-dihydropyrimidin-5-yl)-
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hexanoate (24). A stirred mixture of 6-ethyl 1,1-bis(2,4,6-trichlorophenyl)hexane-1,1,6-
tricarboxylate (23) (1.40 g, 2.31 mmol) and N,N-diethyl-N'-phenylguanidine (443 mg, 2.31 
mmol) was heated to 150 ˚C for 5 min. After allowing to cool to room temperature the 
viscous brown oil was purified by column chromatography (1:1 ethyl acetate:hexane) to give 
the ester 24 (635 mg, 68%) as a pale yellow oil; IR νmax 2935, 1730, 1595, 1524 cm-1; 1H 
NMR (CDCl3, 300 MHz) δ 7.36 (2H, t, J=7.4 Hz, 3,5-aryl), 7.28 (1H, t, J=7.3 Hz, 4-aryl), 
7.19 (2H, d, J=7.1 Hz, 2,6-aryl), 4.02 (2H, q, J=7.1 Hz, CH2CH3), 2.97 (4H, q, J=6.9 Hz, 
N(CH2CH3)2), 2.33 (2H, t, J=7.5 Hz, CCH2), 2.20 (2H, t, J=7.5 Hz, CH2COOEt), 1.63-1.53 
(2H, m, CH2CH2COOEt), 1.50-1.40 (2H, m, CCH2CH2), 1.36-1.25 (2H, m, CCH2CH2CH2), 
1.15 (3H, t, J=7.1 Hz, CH2CH3), 0.75 (6H, t, J=7.0 Hz, N(CH2CH3)2); 13C NMR (CDCl3, 75 
MHz) δ 174.1 (COOEt), 165.1 (4-pyrimidyl), 163.7 (6-pyrimidyl), 155.5 (2-pyrimidyl), 138.1 
(1-aryl), 128.9 (3,5-aryl), 128.8 (2,6-aryl), 128.0 (4-aryl), 95.1 (5-pyrimidyl), 60.1 (CH2CH3), 
44.6 (N(CH2CH3)2), 34.4 (CH2COOEt), 29.1 (CCH2CH2CH2), 27.9 (CHCH2CH2), 24.9 
(CH2CH2COOEt), 23.1 (CCH2), 14.2 (CH2CH3), 12.4 (N(CH2CH3)2); m/z (EI, %) 401 (M+, 2), 
291 (27), 171 (59), 125 (100); HRMS calcd for C22H31N3O4 401.2314. Found: 401.2311. 
6-(2-(Diethylamino)-4-hydroxy-6-oxo-1-phenyl-1,6-dihydropyrimidin-5-yl)-N-hydroxy-
hexanamide (25). To a stirred solution of ethyl 6-(2-(diethylamino)-4-hydroxy-6-oxo-1-
phenyl-1,6-dihydropyrimidin-5-yl)hexanoate (24) (250 mg, 0.62 mmol) in tetrahydrofuran (6 
mL) was added 50% aqueous hydroxylamine (0.41 mL, 6.23 mmol) followed by dropwise 
addition of 1 M potassium hydroxide in methanol (1.87 mL). The mixture was stirred for 5 
min then evaporated and water (20 mL) added to the residue. The mixture was neutralised 
with 1 M hydrochloric acid then extracted with ethyl acetate (4 x 20 mL). The combined 
organic layers were dried (Na2SO4), filtered and evaporated to give an orange oil which was 
purified by column chromatography (ethyl acetate) to give the hydroxamic acid 25 (124 mg, 
51%) as an orange oil; IR νmax 3192, 2932, 1616, 1522 cm-1; 1H NMR (CD3OD, 300 MHz) δ 
7.62-7.38 (3H, m, 3,4,5-aryl), 7.27 (2H, d, J=7.0 Hz, 2,6-aryl), 3.08 (4H, q, J=7.0 Hz, 
N(CH2CH3)2), 2.36 (2H, t, J=7.5 Hz, CH2CO), 2.07 (2H, t, J=7.5 Hz, CCH2), 1.62 (2H, dt, 
J=15.0, 7.5 Hz, CH2CH2CO), 1.57-1.25 (4H, m, CH2CH2CH2CH2CO, CH2CH2CH2CO), 0.80 
(6H, t, J=7.0 Hz, N(CH2CH3)2); 13C NMR (CD3OD, 75 MHz) δ 173.2 (4-pyrimidyl), 167.7 
(CONHOH), 167.2 (6-pyrimidyl), 160.0 (2-pyrimidyl), 139.9 (1-aryl), 130.3 (3,5-aryl), 130.2 
(2,6-aryl), 129.3 (4-aryl), 95.8 (5-pyrimidyl), 46.0 (N(CH2CH3)2), 33.7 (CH2CO), 30.0 
(CH2CH2CH2CO), 29.0 (CH2CH2CH2CH2CO), 26.7 (CH2CH2CO), 23.9 (CCH2), 12.9 
(N(CH2CH3)2); m/z (CI, %) 411 (M+Na, 100), 389 (M+H, 65), 321 (17), 192 (70). HRMS 
calcd for C20H28N4O4 (M+H) 389.2183, found 389.2198. 
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Legends 
Figure 1. FDA-approved HDAC inhibitors. 
 
Scheme 1. Synthesis of a symmetrical bis-malonamide hydroxamic acid.14 Reagents and conditions:  
a NaH (1.1 equiv.) first added to di-tert-butyl malonate (1 equiv.), THF, 20 °C, 20 min then reflux,  
  16 h, 74%. 
b CF3CO2H (6 equiv.), CH2Cl2, 20 °C, 16 h, 99%. 
c SOCl2 (6 equiv.), benzene, reflux, 2 h14 then  
d PhNH2 (6 equiv.), pyridine (3 equiv.), CH2Cl2, 20 °C, 17 h, 76%.14  
e NaOMe, (3 equiv.) and HONH2 (2 equiv.), MeOH, 20 °C, 16 h, 68%.14  
 
Scheme 2. Synthesis of branched derivatives of SAHA. Reagents and conditions:  
a NaH (1.1 equiv.), ethyl 6-bromohexanoate (1 equiv.), THF, 70 °C, 18 h, 74%. 
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b 50% aqueous HONH2 (10 equiv.), 1 M KOH in MeOH, THF, 20 °C, 1 h, 29%. 
c 1:1 CF3CO2H:CH2Cl2, 20 °C, 6 h, 80%. 
d ClCO2Et (1.5 equiv.), Et3N (1.2 equiv), THF, 0 °C, 30 min then NaBH4 (3 equiv.),21 MeOH, 10 °C,  
  1.5 h, 77%. 
e Aqueous 50% HONH2 (5 equiv.), 1M KOH in MeOH, THF, 20 °C, 1.5 h, 12%. 
f 1:1 CF3CO2H:CH2Cl2, 20 °C, 30 min, 80%. 
 
Scheme 3. Synthesis of a branched 2-benzimidazolinyl derivative of SAHA. Reagents and conditions:  
a tert-Butyl N-(2-aminophenyl)carbamate (1 equiv.), EDC.HCl (1.1 equiv.), HOBt (1.1 equiv.), Et3N 
  (2.2 equiv), DMF, 20 °C, 18 h, 66%. 
b AcOH, reflux, 100 °C, 1 h, 77%. 
c Di-tert-butyl dicarbonate (1.5 equiv.), THF, 20 °C, 7 d, 64% conversion. 
d 50% aqueous HONH2 (10 equiv.), 1 M KOH in MeOH, THF, 20 °C, 6 h, 50%. 
 
Scheme 4. Synthesis of a branched hydroxamic acid with a 2-benzimidazolyl capping group. Reagents 
and conditions: 
a 1,2-Phenylenediamine (1 equiv.), N,N’-dicyclohexylcarbodiimide (1.1 equiv.), MeCN, 20 °C, 20 min,  
  50%. 
b AcOH, 90 °C, 1 h, 96%. 
c Di-tert-butyl dicarbonate (1.2 equiv.), THF, 20 °C, 3 d, 97%. 
d NaH (1.1 equiv.), THF, 60 °C, 18 h, 33%. 
e 50% aqueous HONH2 (10 equiv.), 1 M KOH in MeOH, THF, 20 °C, 30 min, 67%. 
 
Scheme 5. Succinct synthesis of a linear hydroxamic acid with a 2-benzimidazolyl capping group. 
Reagents and conditions:  
a Suberic anhydride (1 equiv.), THF, 20 °C, 20 min; then 4% conc. H2SO4 in EtOH, 29%. 
b Aqueous 50% HONH2, 1 M KOH in MeOH, THF, 20 °C, 6 h, 61%. 
 
Scheme 6. Synthesis of a SAHA analog constrained by annulation. Reagents and conditions:  
a CF3CO2H (6 equiv.), CH2Cl2, 20 °C, 24 h, 99%. 
b 2,4,6-Trichlorophenol (2 equiv.), POCl3 (2.6 equiv.), 100 °C, 5 h, 49%. 
c N,N-Diethyl-N’-phenylguanidine (1 equiv.), 5 min, 150 °C, 68%. 
d Aqueous 50% HONH2 (10 equiv.), 1M KOH in MeOH, THF, 20 °C, 2 h, 51%. 
 
